NewLink Genetics Corp. set the expected range of its initial public offering of 5.5 million shares at $10 to $12 a share. The biotechnology company said its lead drug candidate to treat pancreatic cancer is in late-stage trials and it hopes to use the funds raised to help complete the testing. NewLink, which is performing the trial under a special protocol assessment from the Food and Drug Administration, also has received fast-track and orphan-drug designations that help speed the process.
